Libvatrep is under clinical development by Novartis and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Libvatrep’s likelihood of approval (LoA) and phase transition for Ocular Pain (Eye Pain) took place on 07 Jun 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Libvatrep Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Libvatrep (SAF-312) is under development for the treatment of postoperative or chronic ocular surface ocular pain. The drug candidate is administered through oral route and opthalmic route. It is a new molecular entity (NME).
It was also under development for the treatment of postoperative dental pain and neurogenic detrusor overactivity due to spinal cord lesions.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
Quick View Libvatrep LOA Data
|Highest Development Stage|